Skip to main content Skip to search Skip to main navigation

MedTech Europe: Vision for MDR/IVDR Reform

On 7 November 2023, MedTech Europe published a position paper on the Medical Devices Regulation (MDR (EU) 2017/745) and the In Vitro Diagnostic Medical Devices Regulation (IVDR (EU) 2017/746). In the report, the association presents its vision for a regulated legal framework and outlines possible solutions to the ongoing challenges, which have not been overcome after the implementation phase of the MDR and IVDR.

The 12-page position paper, "The Future of Europe's Medical Technology Regulations", follows an open letter from MedTech Europe, together with 34 national associations, to the EU Health Commissioner in September (we reported).
The association once again calls for a fundamental reform and for structural changes to the two regulations so that both patients and European healthcare systems can benefit.

The reform should focus on the three key areas efficiency, innovation and governance while maintaining the high level of safety and performance of the regulations. For each of the three key areas, MedTech Europe identifies principles for success and proposes a number of solutions. These include:

  • An efficient CE marking system that improves predictability, reduces administrative burden, and adapts to external changes.
  •  A system that works for innovation with the inclusion of an innovation principle that swiftly connects the latest medical technologies to European patients and health systems through dedicated assessment pathways and early dialogues with developers.
  • An accountable governance structure with the establishment of a single, dedicated structure to oversee and manage the regulatory system, including the designation and oversight of Notified Bodies, with the authority to make system-level decisions.

The need for all stakeholders to work closely together to achieve the original objectives of IVDR and MDR is explicitly emphasized, as it was already in the open letter.


Source:

MedTech Europe: Position Paper

Meet the GMP Compliance Adviser

The GMP Compliance Adviser is the world's largest knowledge portal for quality management in the pharma business. 

The demo access is non-binding and ends automatically.

Test it now for free

You may also be Interested in the Following Articles:

EMA: New Q&A on Product Lifecycle Management (PLCM)

EMA: New Q&A on Product Lifecycle Management (PLCM)

The EMA has published new Questions & Answers on the use of the Product Lifecycle Management (PLCM) document, clarifying its role within the EU variations framework for post-approval quality changes.
Read more
EMA: New Q&A for Co-Processed Excipients

EMA: New Q&A for Co-Processed Excipients

The EMA has published new Questions & Answers on co-processed excipients (CoPEs) used in solid oral dosage forms, introducing a harmonised, risk-based regulatory approach applicable to human and veterinary medicines.

Read more
What is the Data Lifecycle?

What is the Data Lifecycle?

Here's the answer:
Read more
GMP Regulations Report 2025

GMP Regulations Report 2025

What do the regulatory developments mean for your professional environment? Which requirements have a direct impact on your day-to-day work, and where is there an urgent need for action? Our GMP Regulations Report 2025 provides a clear structure, practical explanations, and the most important regulatory developments of 2025 – concise, well-organized, and relevant.
Read more
EU: Parliament Approves Regulation Proposal on Critical Medicines

EU: Parliament Approves Regulation Proposal on Critical Medicines

The European Parliament has approved regulatory measures aimed at strengthening the availability and supply of critical medicines in the EU.
Read more
What is a gas?

What is a gas?

You can view the answer here:
Read more
Previous
Next